Results 171 to 177 of about 2,330 (177)

Nontuberculous mycobacterial pulmonary infections in the era of elexacaftor-tezacaftor-ivacaftor

Journal of Cystic Fibrosis
Christina M. Mingora, Lindsay J. Caverly
openaire   +2 more sources

Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Adults and Adolescents with Cystic Fibrosis and at Least One F508del Allele: A Phase 3 Open-Label Extension Study

American Journal of Respiratory and Critical Care Medicine
Hiran Selvadurai, Bonnie Ramsey
exaly  

Nasal Epithelium Transcriptomics Predict Clinical Response to Elexacaftor/Tezacaftor/Ivacaftor

American Journal of Respiratory Cell and Molecular Biology
Daniel J Weiner, Franziska Rosser, Joseph M․ Pilewski   +2 more
exaly  

Transforming cystic fibrosis care: the impact of elexacaftor/tezacaftor/ivacaftor

European Respiratory Journal
Alexander Moeller, Elias Seidl
openaire   +2 more sources

Cystic fibrosis: desensitization in delayed hypersensitivity reactions to elexacaftor/tezacaftor/ivacaftor

Frontiers in Pharmacology
E Polverino
exaly  

Adverse events to elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis due to elevated drug exposure?: A case series

Journal of Cystic Fibrosis
Renske Van Der Meer
exaly  

494 Pharmacokinetics of elexacaftor/tezacaftor/ivacaftor with concomitant rifabutin

Journal of Cystic Fibrosis
M. Sanders, E. Hong, P. Chung, A. Rao, P. Beringer   +4 more
openaire   +1 more source